- Report
- November 2026
- 221 Pages
Global
From €5496EUR$5,850USD£4,584GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4218EUR$4,490USD£3,519GBP
- Report
- May 2026
- 185 Pages
Global
From €4228EUR$4,500USD£3,526GBP
- Report
- July 2026
- 224 Pages
Global
From €7507EUR$7,990USD£6,261GBP
- Report
- July 2026
- 244 Pages
Global
From €7507EUR$7,990USD£6,261GBP
- Report
- August 2026
- 110 Pages
Global
From €4463EUR$4,750USD£3,722GBP
- Report
- July 2026
- 130 Pages
Global
From €4463EUR$4,750USD£3,722GBP

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more